Fulcrum Therapeutics Inc.

27.45+0.7100+2.66%Vol 683.51K1Y Perf 256.52%
Sep 24th, 2021 16:00 DELAYED
BID27.38 ASK27.41
Open26.87 Previous Close26.74
Pre-Market- After-Market-
 - -  - -%
Target Price
36.33 
Analyst Rating
Strong Buy 1.13
Potential %
32.35 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★+     53.09
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
78.48 
Earnings Rating
Market Cap1.11B 
Earnings Date
9th Nov 2021
Alpha0.12 Standard Deviation0.68
Beta1.38 

Today's Price Range

26.3628.35

52W Range

6.8533.10

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
-10.96%
1 Month
1.10%
3 Months
205.00%
6 Months
138.49%
1 Year
256.52%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
FULC27.450.71002.66
AAPL146.920.09000.06
GOOG2 852.6616.13000.57
MSFT299.35-0.2100-0.07
XOM57.590.51000.89
WFC47.920.12000.25
JNJ164.36-0.5000-0.30
FB352.967.00002.02
GE103.800.84000.82
JPM163.041.86001.15
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.65-0.607.69
Q01 2021-0.66-0.5418.18
Q04 2020-0.73-0.6412.33
Q03 2020-0.66-0.70-6.06
Q02 2020-0.80-0.6617.50
Q01 2020-0.75-0.81-8.00
Q04 2019-0.84-0.7115.48
Q03 2019-0.62-0.97-56.45
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date9th Nov 2021
Estimated EPS Next Report-0.65
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume683.51K
Shares Outstanding40.30M
Shares Float25.39M
Trades Count8.65K
Dollar Volume911.93K
Avg. Volume1.28M
Avg. Weekly Volume713.85K
Avg. Monthly Volume648.55K
Avg. Quarterly Volume3.43M

Fulcrum Therapeutics Inc. (NASDAQ: FULC) stock closed at 27.45 per share at the end of the most recent trading day (a 2.66% change compared to the prior day closing price) with a volume of 683.53K shares and market capitalization of 1.11B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 73 people. Fulcrum Therapeutics Inc. CEO is Robert J. Gould.

The one-year performance of Fulcrum Therapeutics Inc. stock is 256.52%, while year-to-date (YTD) performance is 134.42%. FULC stock has a five-year performance of %. Its 52-week range is between 6.85 and 33.1, which gives FULC stock a 52-week price range ratio of 78.48%

Fulcrum Therapeutics Inc. currently has a PE ratio of -12.50, a price-to-book (PB) ratio of 11.20, a price-to-sale (PS) ratio of 81.88, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -51.87%, a ROC of -62.94% and a ROE of -62.94%. The company’s profit margin is -%, its EBITDA margin is -466.10%, and its revenue ttm is $15.24 Million , which makes it $0.38 revenue per share.

Of the last four earnings reports from Fulcrum Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.65 for the next earnings report. Fulcrum Therapeutics Inc.’s next earnings report date is 09th Nov 2021.

The consensus rating of Wall Street analysts for Fulcrum Therapeutics Inc. is Strong Buy (1.13), with a target price of $36.33, which is +32.35% compared to the current price. The earnings rating for Fulcrum Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Fulcrum Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Fulcrum Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 11.11, ATR14 : 2.58, CCI20 : -38.18, Chaikin Money Flow : 0.05, MACD : 2.03, Money Flow Index : 68.65, ROC : 1.78, RSI : 55.58, STOCH (14,3) : 27.56, STOCH RSI : 0.12, UO : 51.33, Williams %R : -72.44), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Fulcrum Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (75.00 %)
3 (75.00 %)
3 (75.00 %)
Moderate Buy
1 (25.00 %)
1 (25.00 %)
1 (25.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.13
Strong Buy
1.13
Strong Buy
1.13

Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. It has developed a proprietary product engine that employs to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle-wasting disorder that leads to physical impairments and disability.

CEO: Robert J. Gould

Telephone: +1 617 651-8851

Address: 26 Landsdowne Street, Cambridge 02139, MA, US

Number of employees: 73

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

53%47%

Bearish Bullish

56%44%

TipRanks News for FULC

Tue, 17 Aug 2021 10:25 GMT Analysts Offer Insights on Healthcare Companies: Fulcrum Therapeutics (FULC) and Kronos Bio (KRON)

- TipRanks. All rights reserved.

Mon, 16 Aug 2021 15:51 GMT Is Fulcrum Stock a Buy Right Now This Is What You Need to Know

- TipRanks. All rights reserved.

Fri, 13 Aug 2021 12:27 GMT Leerink Partners Believes Fulcrum Therapeutics (FULC) Still Has Room to Grow

- TipRanks. All rights reserved.

News

Stocktwits